BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24086450)

  • 1. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.
    Young D; Mayer F; Vidotto N; Schweizer T; Berth R; Abramowski D; Shimshek DR; van der Putten PH; Schmid P
    PLoS One; 2013; 8(9):e75108. PubMed ID: 24086450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
    Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
    PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
    Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
    J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
    Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
    Sadri-Vakili G; Menon AS; Farrell LA; Keller-McGandy CE; Cantuti-Castelvetri I; Standaert DG; Augood SJ; Yohrling GJ; Cha JH
    Eur J Neurosci; 2006 Jun; 23(12):3171-5. PubMed ID: 16820007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
    Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
    Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
    Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
    PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.
    Marcellin D; Abramowski D; Young D; Richter J; Weiss A; Marcel A; Maassen J; Kauffmann M; Bibel M; Shimshek DR; Faull RL; Bates GP; Kuhn RR; Van der Putten PH; Schmid P; Lotz GP
    PLoS One; 2012; 7(9):e44457. PubMed ID: 22984513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
    Brown TB; Bogush AI; Ehrlich ME
    Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
    Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
    J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
    Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
    Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.